GH Stack

What is the GH Stack?

The GH Stack is a research bundle of two separate lyophilised reference peptides supplied together as a convenience set: CJC-1295 No DAC (5mg) in one vial and Ipamorelin (5mg) in a second vial. The two compounds are not combined or pre-mixed; each ships as its own sealed vial with its own certificate of analysis. Within the research community this CJC-1295 No DAC and Ipamorelin pairing is commonly referred to as the “GH stack”, and that nickname reflects the part of the literature it sits in (the growth-hormone axis), not any combined effect. Both items are supplied strictly for laboratory research use only and are not licensed medicines.

What is in the GH Stack?

The bundle contains two distinct research peptides, each listed and documented as its own product. CJC-1295 No DAC (also called Modified GRF 1-29) is a synthetic 29-amino-acid analogue of growth-hormone-releasing hormone (GHRH); its chemistry, identifiers and references are on its own listing at CJC-1295 No DAC. Ipamorelin is a synthetic pentapeptide studied as a selective agonist of the growth-hormone secretagogue receptor (GHS-R); its chemistry and references are on its own listing at Ipamorelin. Both sit in the GH-axis research category. Refer to each constituent’s own page for molecular formulae, CAS numbers and identifiers; the bundle does not introduce any new compound. Kovalabs also offers other multi-vial research bundles, including the KLOW Stack and the GLOW Stack.

Is the GH Stack legal in the UK?

Both constituents of the GH Stack are research chemicals. Neither CJC-1295 No DAC nor Ipamorelin is a controlled drug under the Misuse of Drugs Act 1971, and neither is scheduled. The bundle is supplied strictly for in-vitro and laboratory investigation. It is not a licensed medicine, holds no marketing authorisation, and cannot be sold or supplied for human or veterinary consumption. The purchaser is responsible for lawful, compliant handling, storage and disposal under their own institutional and legal obligations. See our research disclaimer for the full terms of supply.

Why are these compounds studied together?

CJC-1295 No DAC and Ipamorelin are frequently referenced in the same body of literature because they act on different parts of the same research area: CJC-1295 No DAC is a GHRH analogue and Ipamorelin is a GHS-R agonist. People often search for them as a pair, which is why this listing exists as a convenience bundle of two reference materials. This co-occurrence in the research area is not evidence of any combined effect in humans, and nothing here implies the compounds work better together, synergise, or produce any benefit or outcome when supplied as a set. The mechanistic detail and the cited studies are covered at research-area level in our CJC-1295 and Ipamorelin research monograph. Nothing on this page or in that monograph constitutes a human claim.

How is quality assured?

Each vial in the GH Stack is treated as its own product and is released only after independent analytical testing. Purity is assessed by HPLC at 99% or higher per vial, and identity is confirmed against the expected mass for each compound. A batch-specific certificate of analysis accompanies each vial, so the CJC-1295 No DAC and the Ipamorelin can be verified independently rather than taken on assertion. Current documents are published on our certificates of analysis page. This per-vial verification is what separates a characterised reference compound from unverified material.

Supply and reconstitution

The GH Stack ships as two separate white to off-white lyophilised solids, one per sealed vial, despatched from the UK. For bench work each peptide is reconstituted independently with a research solvent such as bacteriostatic water, which Kovalabs stocks as a separate research consumable; the vials are not combined as part of supply. Store lyophilised vials at -20C, kept dry and protected from light, and hold any reconstituted material at 2-8C. The milligram strength stated for each vial is a product specification, not a usage instruction, and no guidance on administration to any human or animal is given or implied. Both constituents also sit in the GH-axis category for related research peptides.